PMC:3586680 / 0-279
Annnotations
test3
{"project":"test3","denotations":[{"id":"T41","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T42","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T59","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T60","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T61","span":{"begin":106,"end":109},"obj":"Protein"},{"id":"T43","span":{"begin":106,"end":109},"obj":"Protein"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
testone
{"project":"testone","denotations":[{"id":"T19","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T20","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T21","span":{"begin":106,"end":109},"obj":"Protein"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
bionlp-st-ge-2016-test-tees
{"project":"bionlp-st-ge-2016-test-tees","denotations":[{"id":"T474","span":{"begin":6,"end":21},"obj":"Protein"},{"id":"T475","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T476","span":{"begin":106,"end":109},"obj":"Protein"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
bionlp-st-ge-2016-spacy-parsed
{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T552","span":{"begin":0,"end":5},"obj":"NNP"},{"id":"T553","span":{"begin":6,"end":16},"obj":"NNP"},{"id":"T554","span":{"begin":17,"end":21},"obj":"NNP"},{"id":"T555","span":{"begin":22,"end":25},"obj":"CC"},{"id":"T556","span":{"begin":26,"end":29},"obj":"NN"},{"id":"T557","span":{"begin":30,"end":41},"obj":"NNS"},{"id":"T558","span":{"begin":42,"end":45},"obj":"CC"},{"id":"T559","span":{"begin":46,"end":50},"obj":"NN"},{"id":"T560","span":{"begin":51,"end":61},"obj":"NN"},{"id":"T561","span":{"begin":62,"end":64},"obj":"IN"},{"id":"T562","span":{"begin":65,"end":78},"obj":"NNP"},{"id":"T594","span":{"begin":255,"end":272},"obj":"JJ"},{"id":"T593","span":{"begin":252,"end":254},"obj":"NNP"},{"id":"T592","span":{"begin":250,"end":251},"obj":"."},{"id":"T591","span":{"begin":245,"end":250},"obj":"NNS"},{"id":"T590","span":{"begin":233,"end":244},"obj":"JJ"},{"id":"T589","span":{"begin":229,"end":232},"obj":"CC"},{"id":"T588","span":{"begin":227,"end":228},"obj":"-RRB-"},{"id":"T587","span":{"begin":224,"end":227},"obj":"NNP"},{"id":"T586","span":{"begin":223,"end":224},"obj":"-LRB-"},{"id":"T585","span":{"begin":210,"end":222},"obj":"VB"},{"id":"T584","span":{"begin":207,"end":209},"obj":"TO"},{"id":"T583","span":{"begin":196,"end":206},"obj":"NN"},{"id":"T582","span":{"begin":193,"end":195},"obj":"TO"},{"id":"T581","span":{"begin":191,"end":192},"obj":","},{"id":"T580","span":{"begin":187,"end":191},"obj":"NN"},{"id":"T579","span":{"begin":184,"end":186},"obj":"IN"},{"id":"T578","span":{"begin":182,"end":183},"obj":","},{"id":"T577","span":{"begin":172,"end":182},"obj":"VB"},{"id":"T576","span":{"begin":169,"end":171},"obj":"TO"},{"id":"T575","span":{"begin":161,"end":168},"obj":"VBZ"},{"id":"T574","span":{"begin":157,"end":160},"obj":"CC"},{"id":"T573","span":{"begin":155,"end":156},"obj":"-RRB-"},{"id":"T572","span":{"begin":151,"end":155},"obj":"NNS"},{"id":"T571","span":{"begin":150,"end":151},"obj":"-LRB-"},{"id":"T570","span":{"begin":136,"end":149},"obj":"NNS"},{"id":"T569","span":{"begin":133,"end":135},"obj":"IN"},{"id":"T568","span":{"begin":125,"end":132},"obj":"VBN"},{"id":"T567","span":{"begin":114,"end":124},"obj":"RB"},{"id":"T566","span":{"begin":110,"end":113},"obj":"VBP"},{"id":"T565","span":{"begin":106,"end":109},"obj":"NN"},{"id":"T564","span":{"begin":95,"end":105},"obj":"NN"},{"id":"T563","span":{"begin":89,"end":94},"obj":"NNP"}],"relations":[{"id":"R265","pred":"compound","subj":"T552","obj":"T554"},{"id":"R266","pred":"compound","subj":"T553","obj":"T554"},{"id":"R267","pred":"nsubjpass","subj":"T554","obj":"T568"},{"id":"R268","pred":"cc","subj":"T555","obj":"T554"},{"id":"R269","pred":"compound","subj":"T556","obj":"T557"},{"id":"R270","pred":"conj","subj":"T557","obj":"T554"},{"id":"R271","pred":"cc","subj":"T558","obj":"T557"},{"id":"R272","pred":"compound","subj":"T559","obj":"T560"},{"id":"R273","pred":"conj","subj":"T560","obj":"T557"},{"id":"R274","pred":"prep","subj":"T561","obj":"T557"},{"id":"R275","pred":"compound","subj":"T562","obj":"T565"},{"id":"R276","pred":"compound","subj":"T563","obj":"T565"},{"id":"R277","pred":"compound","subj":"T564","obj":"T565"},{"id":"R278","pred":"pobj","subj":"T565","obj":"T561"},{"id":"R279","pred":"auxpass","subj":"T566","obj":"T568"},{"id":"R280","pred":"advmod","subj":"T567","obj":"T568"},{"id":"R281","pred":"ROOT","subj":"T568","obj":"T568"},{"id":"R282","pred":"prep","subj":"T569","obj":"T568"},{"id":"R283","pred":"pobj","subj":"T570","obj":"T569"},{"id":"R284","pred":"punct","subj":"T571","obj":"T572"},{"id":"R285","pred":"appos","subj":"T572","obj":"T570"},{"id":"R286","pred":"punct","subj":"T573","obj":"T568"},{"id":"R287","pred":"cc","subj":"T574","obj":"T568"},{"id":"R288","pred":"conj","subj":"T575","obj":"T568"},{"id":"R289","pred":"aux","subj":"T576","obj":"T577"},{"id":"R290","pred":"xcomp","subj":"T577","obj":"T575"},{"id":"R291","pred":"punct","subj":"T578","obj":"T577"},{"id":"R292","pred":"prep","subj":"T579","obj":"T575"},{"id":"R293","pred":"pobj","subj":"T580","obj":"T579"},{"id":"R294","pred":"punct","subj":"T581","obj":"T575"},{"id":"R295","pred":"aux","subj":"T582","obj":"T583"},{"id":"R296","pred":"advcl","subj":"T583","obj":"T568"},{"id":"R297","pred":"aux","subj":"T584","obj":"T585"},{"id":"R298","pred":"advcl","subj":"T585","obj":"T583"},{"id":"R299","pred":"punct","subj":"T586","obj":"T587"},{"id":"R300","pred":"appos","subj":"T587","obj":"T585"},{"id":"R301","pred":"punct","subj":"T588","obj":"T587"},{"id":"R302","pred":"cc","subj":"T589","obj":"T585"},{"id":"R303","pred":"amod","subj":"T590","obj":"T591"},{"id":"R304","pred":"conj","subj":"T591","obj":"T585"},{"id":"R305","pred":"punct","subj":"T592","obj":"T568"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
bionlp-st-ge-2016-test-ihmc
{"project":"bionlp-st-ge-2016-test-ihmc","denotations":[{"id":"T529","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T546","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T535","span":{"begin":210,"end":228},"obj":"Entity"},{"id":"T526","span":{"begin":233,"end":250},"obj":"Entity"},{"id":"T525","span":{"begin":89,"end":109},"obj":"Protein"},{"id":"T523","span":{"begin":224,"end":227},"obj":"Entity"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
DLUT931
{"project":"DLUT931","denotations":[{"id":"T397","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T398","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T415","span":{"begin":30,"end":41},"obj":"Regulation"},{"id":"T399","span":{"begin":106,"end":109},"obj":"Protein"}],"relations":[{"id":"R212","pred":"themeOf","subj":"T397","obj":"T415"},{"id":"R213","pred":"themeOf","subj":"T398","obj":"T415"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
BioNLP16_Messiy
{"project":"BioNLP16_Messiy","denotations":[{"id":"T447","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T448","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T465","span":{"begin":30,"end":41},"obj":"Regulation"},{"id":"T449","span":{"begin":106,"end":109},"obj":"Protein"}],"relations":[{"id":"R230","pred":"themeOf","subj":"T448","obj":"T465"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
BioNLP16_DUT
{"project":"BioNLP16_DUT","denotations":[{"id":"T355","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T356","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T357","span":{"begin":106,"end":109},"obj":"Protein"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
bionlp-st-ge-2016-uniprot
{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T390","span":{"begin":26,"end":29},"obj":"http://www.uniprot.org/uniprot/P04637"},{"id":"T396","span":{"begin":89,"end":109},"obj":"http://www.uniprot.org/uniprot/P04637"},{"id":"T391","span":{"begin":106,"end":109},"obj":"http://www.uniprot.org/uniprot/P04637"},{"id":"T381","span":{"begin":17,"end":21},"obj":"http://www.uniprot.org/uniprot/Q9NZC7"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
bionlp-st-ge-2016-test-proteins
{"project":"bionlp-st-ge-2016-test-proteins","denotations":[{"id":"T118","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T119","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T120","span":{"begin":106,"end":109},"obj":"Protein"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
pmc-enju-pas
{"project":"pmc-enju-pas","denotations":[{"id":"T166","span":{"begin":0,"end":5},"obj":"NN"},{"id":"T167","span":{"begin":6,"end":16},"obj":"NN"},{"id":"T168","span":{"begin":17,"end":21},"obj":"NN"},{"id":"T169","span":{"begin":22,"end":25},"obj":"CC"},{"id":"T170","span":{"begin":26,"end":29},"obj":"NN"},{"id":"T171","span":{"begin":30,"end":41},"obj":"NN"},{"id":"T172","span":{"begin":42,"end":45},"obj":"CC"},{"id":"T173","span":{"begin":46,"end":50},"obj":"NNP"},{"id":"T174","span":{"begin":51,"end":61},"obj":"NNP"},{"id":"T175","span":{"begin":62,"end":64},"obj":"IN"},{"id":"T176","span":{"begin":65,"end":78},"obj":"NN"},{"id":"T207","span":{"begin":255,"end":272},"obj":"JJ"},{"id":"T206","span":{"begin":252,"end":254},"obj":"JJ"},{"id":"T205","span":{"begin":245,"end":250},"obj":"NN"},{"id":"T204","span":{"begin":233,"end":244},"obj":"JJ"},{"id":"T203","span":{"begin":229,"end":232},"obj":"CC"},{"id":"T202","span":{"begin":227,"end":228},"obj":"-RRB-"},{"id":"T201","span":{"begin":224,"end":227},"obj":"NN"},{"id":"T200","span":{"begin":223,"end":224},"obj":"-LRB-"},{"id":"T199","span":{"begin":210,"end":222},"obj":"NN"},{"id":"T198","span":{"begin":207,"end":209},"obj":"TO"},{"id":"T197","span":{"begin":196,"end":206},"obj":"NN"},{"id":"T196","span":{"begin":193,"end":195},"obj":"TO"},{"id":"T195","span":{"begin":191,"end":192},"obj":"-COMMA-"},{"id":"T194","span":{"begin":187,"end":191},"obj":"NN"},{"id":"T193","span":{"begin":184,"end":186},"obj":"IN"},{"id":"T192","span":{"begin":182,"end":183},"obj":"-COMMA-"},{"id":"T191","span":{"begin":172,"end":182},"obj":"VB"},{"id":"T190","span":{"begin":169,"end":171},"obj":"TO"},{"id":"T189","span":{"begin":161,"end":168},"obj":"VB"},{"id":"T188","span":{"begin":157,"end":160},"obj":"CC"},{"id":"T187","span":{"begin":155,"end":156},"obj":"-RRB-"},{"id":"T186","span":{"begin":151,"end":155},"obj":"NN"},{"id":"T185","span":{"begin":150,"end":151},"obj":"-LRB-"},{"id":"T184","span":{"begin":136,"end":149},"obj":"NN"},{"id":"T183","span":{"begin":133,"end":135},"obj":"IN"},{"id":"T182","span":{"begin":125,"end":132},"obj":"VB"},{"id":"T181","span":{"begin":114,"end":124},"obj":"RB"},{"id":"T180","span":{"begin":110,"end":113},"obj":"VB"},{"id":"T179","span":{"begin":106,"end":109},"obj":"NN"},{"id":"T178","span":{"begin":95,"end":105},"obj":"NN"},{"id":"T177","span":{"begin":89,"end":94},"obj":"NN"}],"relations":[{"id":"R28","pred":"arg1Of","subj":"T168","obj":"T166"},{"id":"R29","pred":"arg1Of","subj":"T168","obj":"T167"},{"id":"R30","pred":"arg1Of","subj":"T168","obj":"T169"},{"id":"R31","pred":"arg1Of","subj":"T169","obj":"T175"},{"id":"R32","pred":"arg1Of","subj":"T171","obj":"T170"},{"id":"R33","pred":"arg1Of","subj":"T171","obj":"T172"},{"id":"R34","pred":"arg2Of","subj":"T172","obj":"T169"},{"id":"R35","pred":"arg2Of","subj":"T174","obj":"T172"},{"id":"R36","pred":"arg1Of","subj":"T174","obj":"T173"},{"id":"R37","pred":"arg2Of","subj":"T176","obj":"T175"},{"id":"R38","pred":"arg1Of","subj":"T179","obj":"T177"},{"id":"R39","pred":"arg1Of","subj":"T179","obj":"T178"},{"id":"R40","pred":"arg1Of","subj":"T179","obj":"T180"},{"id":"R41","pred":"arg2Of","subj":"T179","obj":"T182"},{"id":"R42","pred":"arg1Of","subj":"T179","obj":"T189"},{"id":"R43","pred":"arg1Of","subj":"T179","obj":"T191"},{"id":"R44","pred":"arg2Of","subj":"T182","obj":"T180"},{"id":"R45","pred":"arg1Of","subj":"T182","obj":"T181"},{"id":"R46","pred":"arg1Of","subj":"T182","obj":"T183"},{"id":"R47","pred":"arg1Of","subj":"T182","obj":"T188"},{"id":"R48","pred":"arg2Of","subj":"T184","obj":"T183"},{"id":"R49","pred":"arg1Of","subj":"T184","obj":"T185"},{"id":"R50","pred":"arg2Of","subj":"T186","obj":"T185"},{"id":"R51","pred":"arg3Of","subj":"T187","obj":"T185"},{"id":"R52","pred":"arg2Of","subj":"T189","obj":"T188"},{"id":"R53","pred":"arg2Of","subj":"T191","obj":"T189"},{"id":"R54","pred":"arg1Of","subj":"T191","obj":"T190"},{"id":"R55","pred":"arg1Of","subj":"T191","obj":"T192"},{"id":"R56","pred":"arg1Of","subj":"T191","obj":"T193"},{"id":"R57","pred":"arg1Of","subj":"T191","obj":"T195"},{"id":"R58","pred":"arg1Of","subj":"T191","obj":"T196"},{"id":"R59","pred":"arg2Of","subj":"T194","obj":"T193"},{"id":"R60","pred":"arg1Of","subj":"T197","obj":"T198"},{"id":"R61","pred":"arg1Of","subj":"T197","obj":"T203"},{"id":"R62","pred":"arg2Of","subj":"T199","obj":"T198"},{"id":"R63","pred":"arg1Of","subj":"T199","obj":"T200"},{"id":"R64","pred":"arg2Of","subj":"T201","obj":"T200"},{"id":"R65","pred":"arg3Of","subj":"T202","obj":"T200"},{"id":"R66","pred":"arg2Of","subj":"T203","obj":"T196"},{"id":"R67","pred":"arg2Of","subj":"T205","obj":"T203"},{"id":"R68","pred":"arg1Of","subj":"T205","obj":"T204"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
GO-BP
{"project":"GO-BP","denotations":[{"id":"T136","span":{"begin":0,"end":16},"obj":"http://purl.obolibrary.org/obo/GO_0051726"},{"id":"T139","span":{"begin":46,"end":61},"obj":"http://purl.obolibrary.org/obo/GO_0042493"},{"id":"T137","span":{"begin":89,"end":105},"obj":"http://purl.obolibrary.org/obo/GO_0051726"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
sentences
{"project":"sentences","denotations":[{"id":"T79","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"T80","span":{"begin":89,"end":251},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":78},"obj":"Sentence"},{"id":"T2","span":{"begin":80,"end":88},"obj":"Sentence"},{"id":"T3","span":{"begin":89,"end":251},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}
simple1
{"project":"simple1","denotations":[{"id":"T148","span":{"begin":17,"end":21},"obj":"Protein"},{"id":"T149","span":{"begin":26,"end":29},"obj":"Protein"},{"id":"T150","span":{"begin":106,"end":109},"obj":"Protein"}],"text":"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas\n\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidor"}